logo

Clinical Trial Results

Share

Drug major Pfizer Inc. (PFE) Wednesday announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily ritlecitinib in patients with alopecia areata. It is an autoimmune disease driven by an immune attack on the hair follicles that causes hair loss on the scalp and...

Eli Lilly and Co. (LLY) and Incyte (INCY) Tuesday said that new data from Phase 3 COV-BARRIER sub-study indicated that baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation. As per the data, one death prevented for every six baricitinib-treated patients...

ERYTECH Pharma S.A. (ERYP), a clinical-stage biopharmaceutical company developing red blood-cell based cancer therapeutics, has been granted Fast Track designation for its lead drug candidate, Eryaspase, for the treatment of hypersensitive acute lymphocytic leukemia.

Shares of Vaxart Inc. (VXRT) are up more than 11% at $9.12 in pre-market trading Thursday, following encouraging news from the company's first booster clinical study of its oral norovirus vaccine.

Seres Therapeutics Inc. (MCRB) said that a phase 2b ECO-RESET study, which evaluated SER-287 in patients with mild-to-moderate ulcerative colitis, did not meet its primary endpoint of improving clinical remission rates compared to placebo. Both dosing regimens of SER-287 were generally well tolerated. In...

Bristol Myers Squibb (BMY) said that phase 3 CheckMate-651 trial, which evaluated opdivo or nivolumab plus yervoy or ipilimumab versus EXTREME Regimen as First-Line Treatment for Squamous Cell Carcinoma of the Head and Neck, did not meet its primary endpoints. The study results showed a clear, positive...

Eli Lilly and Co. (LLY) announced Friday new Phase 2 data showing that gene expression changes induced by mirikizumab in patients with ulcerative colitis or UC over a 12-week induction treatment were maintained for up to one year. These gene transcript changes were associated with mucosal healing,...

Pfizer (PFE) and BioNTech (BNTX) announced "encouraging data" from their ongoing trial of a third COVID-19 vaccine dose. A third dose may be beneficial to maintain highest levels of protection from the COVID-19. They plan to submit the data of the booster dose to the FDA, EMA and other regulatory authorities...

Shares of biopharmaceutical company Opiant Pharmaceuticals Inc. (OPNT) are soaring 63 percent higher in Tuesday's after-market trading after the company reported positive top-line results for Nasal Nalmefene, its investigational treatment for Opioid overdose. The company announced encouraging...

Boehringer Ingelheim and Eli Lilly and Co. (LLY) announced Tuesday that the EMPEROR-Preserved phase III trial met its primary endpoint, establishing Jardiance (empagliflozin) as the first and only therapy to significantly reduce the risk of the composite of cardiovascular death or hospitalization for...

Innate Pharma SA (IPHA) announced Tuesday that the investigator-sponsored Avdoralimab Phase 2 FORCE Trial in COVID-19 Patients with severe pneumonia did not meet primary endpoints in all three cohorts of the trial. Based on these results, the company will stop exploring avdoralimab in COVID-19. Meanwhile,...

Follow RTT